Treatment of cancer cells with asparaginase can be augmented by the inhibition of GCN2 (Nakamura et al., 2018), which is a part of the integrated stress response that upregulates amino acid biosynthesis and transport (Ye et al., 2010). The gene discussed is ASPG; the disease is cancer.